Rush Enterprises Plans $100M Stock Buyback

Rush Enterprises Inc (NASDAQ:RUSHA) announced that its Board of Directors approved a new stock repurchase program up to an aggregate of…

byShivani Kumaresan

December 1, 2021

1 minute read

Rush Enterprises Inc (NASDAQ:RUSHA) announced that its Board of Directors approved a new stock repurchase program up to an aggregate of $100 million of its shares.
The new stock repurchase program replaces the prior $100 million stock repurchase program.
As of November 29, 2021, the company had repurchased $30.7 million worth of shares of its common stock under the prior program.
The new stock repurchase program expires on December 31, 2022.
Rush held $259.7 million in cash and equivalents as of September 30, 2021.
Price Action: RUSHA shares closed lower by 3.39% at $50.96 on Tuesday.

PureTech Health To Test LYT-200 / Tislelizumab Combo In Difficult To Treat Cancer

By Vandana Singh

Today, 8:51 PM

PureTech Health plc (NASDAQ:PRTC) has announced a clinical trial and supply agreement with an affiliate of BeiGene Ltd (NASDAQ:BGNE). The partnership will evaluate…

BGNE

Ready For Takeoff? US Bank Launches Crypto Custody

By Adrian Zmudzinski

Today, 8:51 PM

U.S. Bancorp's (NYSE: USB) bank, U.S. Bank, is launching its own cryptocurrency custody service aimed at institutional investors in partnership with New York Digital Investment Group (NYDIG).

BCH

Rush Street Interactive Q2 EPS $(0.04) Beats $(0.12) Estimate, Sales $122.80M Beat $111.34M Estimate

By Michael Horton

Today, 8:51 PM

Rush Street Interactive (NYSE:RSI) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.12) by 66.67 percent. The company reported quarterly sales of $122.80 million which beat

RSI

FDA
News

Merck Receives Positive EU CHMP Opinion For Keytruda Plus Chemotherapy, With Or Without Bevacizumab, As Treatment For Patients With Persistent, Recurrent Or Metastatic Cervical Cancer Whose Tumors Express PD-l1 (cps ≥1)

By Benzinga Newsdesk

Today, 8:51 PM

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending

MRK

Rush Enterprises Plans $100M Stock Buyback

Related Posts

PureTech Health To Test LYT-200 / Tislelizumab Combo In Difficult To Treat Cancer

Ready For Takeoff? US Bank Launches Crypto Custody

Rush Street Interactive Q2 EPS $(0.04) Beats $(0.12) Estimate, Sales $122.80M Beat $111.34M Estimate

Merck Receives Positive EU CHMP Opinion For Keytruda Plus Chemotherapy, With Or Without Bevacizumab, As Treatment For Patients With Persistent, Recurrent Or Metastatic Cervical Cancer Whose Tumors Express PD-l1 (cps ≥1)